Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Gross Margin (2016 - 2019)

Aptevo Therapeutics (APVO) has disclosed Gross Margin for 5 consecutive years, with 32.06% as the latest value for Q4 2019.

  • Quarterly Gross Margin changed N/A to 32.06% in Q4 2019 from the year-ago period, while the trailing twelve-month figure was 38.54% through Dec 2019, changed N/A year-over-year, with the annual reading at 38.54% for FY2019, 1284.0% down from the prior year.
  • Gross Margin hit 32.06% in Q4 2019 for Aptevo Therapeutics, down from 56.06% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 77.22% in Q1 2017 to a low of 67.24% in Q2 2017.
  • Historically, Gross Margin has averaged 36.28% across 5 years, with a median of 45.22% in 2019.
  • Biggest five-year swings in Gross Margin: tumbled -10283bps in 2017 and later soared 13012bps in 2018.
  • Year by year, Gross Margin stood at 36.8% in 2015, then grew by 14bps to 42.07% in 2016, then skyrocketed by 66bps to 69.67% in 2017, then dropped by -17bps to 58.16% in 2018, then tumbled by -45bps to 32.06% in 2019.
  • Business Quant data shows Gross Margin for APVO at 32.06% in Q4 2019, 56.06% in Q3 2019, and 18.68% in Q2 2019.